| Nov 6 |
Acadia: Q3 Earnings Snapshot
|
| Nov 6 |
Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M
|
| Nov 6 |
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
|
| Nov 5 |
Acadia Pharma Q3 2024 Earnings Preview
|
| Nov 5 |
Acadia sells Rare Pediatric Disease Priority Review Voucher for $150M
|
| Nov 5 |
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
|
| Oct 31 |
ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
|
| Oct 17 |
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
|
| Oct 17 |
Health Canada approves Acadia’s DAYBUE for Rett syndrome
|
| Oct 16 |
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
|
